Publications by authors named "M de Monte"
Breast cancer represents the primary cause of death of women under 65 in developed countries, due to the acquisition of multiple drug resistance mechanisms. The PI3K/AKT pathway is one of the major regulating mechanisms altered during the development of endocrine resistance and inhibition of steps in this signalling pathway are adopted as a key strategy to overcome this issue. ADP-ribosylation is a post-translational modification catalysed by PARP enzymes that regulates essential cellular processes, often altered in diseases.
View Article and Find Full Text PDFArticle Synopsis
- - Cholestatic liver diseases (CLD) cause damage to the liver cells and can lead to fibrosis and cirrhosis due to bile acid accumulation, with STARD1 playing a potential role in this process.
- - Research found that patients with primary biliary cholangitis had higher STARD1 levels, and mice lacking STARD1 specifically in liver cells were more resistant to liver damage and inflammation associated with bile duct blockage.
- - The study suggests that targeting STARD1 could be a promising approach for treating cholestatic liver injury, as it appears to influence bile acid levels and oxidative stress in liver cells.
Cardiotoxicity is the serious side effect of doxorubicin treatment. Ceramides are formed from the degradation of sphingolipids in cell membranes and play an important role in signaling and modulating biological processes. There is evidence that omega-3 fatty acid administration can act on this pathway.
View Article and Find Full Text PDFAfter major abdominal surgery and open hysterectomy, postoperative pain management is often challenging. Various abdominal fascial and truncal blocks, including paravertebral, erector spinae plane, transversus abdominis plane, and quadratus lumborum blocks, have been evaluated for their efficacy. When used in a multimodal pain control strategy, after an open abdominal hysterectomy under spinal anesthesia, the novel sacral erector spinae plane block showed promising results in terms of safety, efficacy, and minimal invasiveness.
View Article and Find Full Text PDFArticle Synopsis
- Metabolic dysfunction-associated steatohepatitis (MASH) is a significant health issue linked to liver fat buildup and serious complications like cirrhosis and liver cancer.
- A study tested non-mitogenic FGF19 mRNA delivered in liver-targeted nanoparticles on mice with diet-induced obesity and MASH, finding it led to weight loss, improved insulin sensitivity, and reversal of MASH symptoms without worsening liver fibrosis.
- The treatment also altered liver bile acid levels, which may affect fat absorption and overall metabolism, suggesting promising prospects for mRNA-based therapies in treating MASH and related metabolic disorders.